Tegaserod maleate

Cat. No.: HY-14153A
CAS No.: 189188-57-6
Molecular Formula: Cₒ₀H₂₇N₅O₅
Molecular Weight: 417.46
Target: 5-HT Receptor
Pathway: GPCR/G Protein; Neuronal Signaling
Storage: Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

<table>
<thead>
<tr>
<th>Solvent</th>
<th>Concentration</th>
<th>Mass</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td>≥ 35 mg/mL</td>
<td>(83.84 mM) *</td>
</tr>
</tbody>
</table>

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.3954 mL</td>
<td>11.9772 mL</td>
<td>23.9544 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4791 mL</td>
<td>2.3954 mL</td>
<td>4.7909 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2395 mL</td>
<td>1.1977 mL</td>
<td>2.3954 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Tegaserod maleate is a partial agonist of the 5-HT4 receptor; stimulates the peristaltic reflex and accelerates gastrointestinal transit. IC50 value: Target: 5-HT4 agonist. In an in vivo model for peripheral nerve regeneration, mice receiving tegaserod at the site of injury showed enhanced recovery compared to control mice receiving vehicle control as evidenced by functional measurements and histology [1]. Treatment with fluoxetine (10 mg · kg(-1) · day(-1), days 36-42), tegaserod (1 mg · kg(-1) · day(-1), day 43), or the combination of both, reduced visceral hypersensitivity and plasma 5-HT levels [2]. Intravenous or intraduodenal tegaserod (0.3-1.0 mg.kg(-1)) had no inhibitory effect on mesenteric and colonic blood flow. Peroral treatment of rats with alosetron or tegaserod for 7 days did not modify mesenteric haemodynamics at baseline and after blockade of nitric oxide synthesis [3].

REFERENCES
